EANS-Adhoc: AGENNIX AG /

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Loan agreement

23.07.2010

Agennix AG Secures E 15 Million Loan

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 23,
2010 - Agennix AG (Frankfurt Stock Exchange: AGX) today announced
that it has entered into an agreement with one of its major
shareholders, dievini Hopp BioTech holding GmbH & Co. KG, pursuant to
which dievini Hopp BioTech has provided a E 15.0 million loan to
Agennix at an interest rate of 6% per annum. The loan agreement is
unsecured and is repayable on thirty days advance notice, but not
before October 15, 2010.

end of ad-hoc-announcement ==========================================
====================================== About Agennix Agennix AG is a
publicly listed biopharmaceutical company that is focused on the
development of novel therapies to improve the length and quality of
life of seriously ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase 1 testing; the oral
platinum-based compound satraplatin; and a topical gel form of
talactoferrin for diabetic foot ulcers. Agennix's registered seat is
in Heidelberg, Germany. The Company has three sites of operation:
Martinsried/Munich, Germany; Princeton, New Jersey and Houston,
Texas. For additional information, please visit the Agennix Web site
at www.agennix.com.

This ad hoc announcement contains forward-looking statements, which
express the current beliefs and expectations of the management of
Agennix AG. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this ad hoc announcement.
Forward-looking statements speak only as of the date on which they
are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Agennix AG

Investor Relations & Corporate Communications

Phone: +49 (0)89 8565 2693

ir@agennix.com

In the U.S.: Laurie Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884

laurie.doyle@agennix.com

Additional media contacts for Europe:

MC Services AG

Phone: +49 (0) 89 210 228 0

Raimund Gabriel

raimund.gabriel@mc-services.eu

Hilda Juhasz

hilda.juhasz@mc-services.eu

Additional investor contact for Europe:

Trout International LLC

Lauren (Rigg) Williams, Vice President

Phone: +44 207 936 9325

lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade